News

Public · Published

Vivos Inc. Announces Expansion of IsoPet® Animal Cancer Division with Four New Veterinary Clinics Across the United States

Vivos Inc., a medical device company, announced that four additional veterinary facilities are advancing through certification, licensing, and onboarding to offer IsoPet® cancer treatment for animals, expanding its IsoPet® Animal Cancer Division across the United States.

Published:

Updated:

What happened

Vivos Inc., a medical device company, announced that four additional veterinary facilities are advancing through certification, licensing, and onboarding to offer IsoPet® cancer treatment for animals, expanding its IsoPet® Animal Cancer Division across the United States.

Confirmed

Global impact / market context

Adding treatment sites can bring more animals into IsoPet® care, which may create recurring product demand and support revenue growth. Each certified clinic adds clinical capacity and reach, helping Vivos build the infrastructure needed to handle higher treatment volumes over time.

Analyst inference

Vivos trades over the counter under RDGL, which means its shares are not listed on a major exchange and can be less liquid. Expansion news for a small device company signals execution on its animal health strategy rather than proof of sales or profit.

Analyst inference

What to watch

  1. Track whether the four named veterinary facilities complete certification, licensing, and onboarding, since the company says they are still advancing through that process rather than already offering treatment. Confirmed
  2. Watch for signs of actual treatment volumes and recurring product orders at certified clinics, because those would show whether added sites translate into revenue rather than capacity alone. Analyst inference
  3. Consider monitoring whether Vivos announces further clinic additions or updates on certification progress, which would indicate the pace of its stated strategy to broaden access to IsoPet® therapy. Proposed

Evidence